Clinical Trials Browser

Pathologic Complete Response

Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Resectable Colon Cancer

Biliary Tract Neoplasms

Cholangiocarcinoma

Solid Tumors

Colorectal Neoplasms

Colorectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Colorectal Neoplasms

Pancreatic Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Advanced Solid Tumor

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Locally Advanced Low Rectal Adenocarcinoma

Appendiceal Neoplasms, Colorectal Neoplasms

Pancreatic Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Pancreatic Cancer Resectable

Stomach Neoplasms

Biliary Cancer Metastatic

PDAC - Pancreatic Ductal Adenocarcinoma

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Colonic Neoplasms

Biliary Tract Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Liver Metastases of Colorectal Cancer

Gastroesophageal Junction Cancer

Liver Neoplasms

Efficacy and Safety

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Rectal Neoplasms

Colorectal Neoplasms, Neoplasm, Residual

Colorectal Neoplasms, Neoplasms, Second Primary

Clinical Trials

MEND-IT II

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

CROCOBIL

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

ARIEL-ENGIC

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

FOXHIPECT4

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

LEFT-PANC

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

PANORAMIX

FIRE-11

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Pre-Operative Treatment in REseCTable COlon CanceR

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

FD-IMPACT

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

AFFORD

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation